Harnessing diversity to study Alzheimer's disease: A new iPSC resource from the NIH CARD and ADNI.

The iDA Project (iPSCs to Study Diversity in Alzheimer's and Alzheimer's Disease-related Dementias) is generating 200 induced pluripotent stem cell lines from Alzheimer's Disease Neuroimaging Initiative participants. These lines are sex balanced, include common APOE genotypes, span disease stages, and are ancestrally diverse. Cell lines and characterization data will be shared openly.
Competing Interests: Declaration of interests A.J.S. has received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in-kind contribution of PET tracer precursor), and has participated in scientific advisory boards (Bayer Oncology, Eisai, Novo Nordisk, and Siemens Medical Solutions USA, Inc) and an observational study monitoring board (MESA, NIH NHLBI). He also serves as editor-in-chief for Brain Imaging and Behavior, a Springer-Nature journal, and serves on four other NIA external advisory committees. M.A.N. currently serves on the scientific advisory board for Character Bio Inc. and is a scientific founder at Neuron23 Inc.
(Published by Elsevier Inc.)